Investing.com -- Tesla stock edged higher premarket after a report from Reuters said the company is developing an all-new compact electric SUV that would be smaller and cheaper than its existing lineup.
Investing.com -- Tesla stock edged higher premarket after a report from Reuters said the company is developing an all-new compact electric SUV that would be smaller and cheaper than its existing lineup.
The United States market has shown robust performance, rising 3.0% over the last week and achieving a 26% increase over the past year, with earnings projected to grow by 16% annually. In such a thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business's operations and potential.
The United States market has shown robust performance, rising 3.0% over the last week and achieving a 26% increase over the past year, with earnings projected to grow by 16% annually. In such a thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business's operations and potential.
Belgian spacetech EDGX has successfully launched its first in-orbit demonstration of STERNA, an AI-powered edge computer for satellite constellations aboard SpaceX's Transporter-16 mission. With two hosted payloads now in orbit, EDGX enables real-time data processing directly in space, a critical capability for next-generation satellite constellations across commercial, governmental, and defence a...
Belgian spacetech EDGX has successfully launched its first in-orbit demonstration of STERNA, an AI-powered edge computer for satellite constellations aboard SpaceX's Transporter-16 mission. With two hosted payloads now in orbit, EDGX enables real-time data processing directly in space, a critical capability for next-generation satellite constellations across commercial, governmental, and defence applications.
ElenVD/iStock via Getty Images NioCorp Developments ( NB ) has entered into a non-binding agreement with Traxys North America LLC outlining a long-term marketing and offtake arrangement for NioCorp's remaining planned critical minerals products from its Elk Creek Critical Minerals Project. Subject to a definitive contract being executed between NioCorp and Traxys, NioCorp would be positioned to se...
ElenVD/iStock via Getty Images NioCorp Developments ( NB ) has entered into a non-binding agreement with Traxys North America LLC outlining a long-term marketing and offtake arrangement for NioCorp's remaining planned critical minerals products from its Elk Creek Critical Minerals Project. Subject to a definitive contract being executed between NioCorp and Traxys, NioCorp would be positioned to sell out of its planned critical minerals products for the first 10 years of operation, following the successful completion of project financing and commencement of commercial production. NioCorp has already placed under contract 75% of its planned ferroniobium production and 12% of its planned scandium oxide production. The company's shares rose 2.2% in early trading. Traxys could also become a shareholder of NioCorp ( NB ) while playing a key role in President Trump's recently announced Project Vault, which aims to facilitate sales of critical minerals between large manufacturers and critical mineral producers. "Upon execution of definitive agreements with Traxys, we believe that this initiative moves NioCorp closer to securing full project financing for the Elk Creek Project," said Mark A. Smith , CEO, and Executive Chairman of NioCorp. "Together with our existing offtake agreement with ThyssenKrupp ( TYEKF ) for 50% of our planned ferroniobium production during the first 10 years of operations, a definitive deal with Traxys would lead to the sale of all our remaining planned products for the first 10 years of operations." Traxys currently has commercial offtake agreements covering 25% of the company's planned ferroniobium production and up to 12% of its planned scandium production, both over the first 10 years of NioCorp's operations. Under the proposed offtake agreement, this relationship would be expanded to include an additional 25% of the planned ferroniobium production on a take-or-pay basis and the remaining scandium production, as well as 100% of planned production...
Investors that slashed their stock exposure as war flared in the Middle East may soon have a fresh reason for piling back into equities: the upcoming earnings season. Analysts have been boosting their estimates of Corporate America’s profitability, even as uncertainty fueled by the Iran war spurred volatility in markets. The recent selloff also pushed stock valuations to their lowest levels in aro...
Investors that slashed their stock exposure as war flared in the Middle East may soon have a fresh reason for piling back into equities: the upcoming earnings season. Analysts have been boosting their estimates of Corporate America’s profitability, even as uncertainty fueled by the Iran war spurred volatility in markets. The recent selloff also pushed stock valuations to their lowest levels in around a year, further bolstering the case for investors to put money back to work. “Wall Street’s expectations for the first quarter are pretty high,” said Marshall Front , chief investment officer at Front Barnett Associates. Investors who reduced stock exposure “ought to consider reestablishing some of those equity positions that they exited.” The focus on earnings season — which kicks off next week — comes as investors take stock of the market landscape following a still-fragile ceasefire between the US and Iran that sent markets roaring higher on Wednesday. While oil prices remain elevated and the trajectory of the conflict is unclear, bullish investors have pointed to robust corporate earnings expectations as a key reason to remain constructive on equities. Analysts now expect S&P 500 companies will report a 12.5% profit growth in the three months through March, compared to an estimate of 10.9% before the war started, data compiled by Bloomberg Intelligence show. At the same time, the S&P 500’s forward price-to-earnings ratio fell just below 19 at the end of March, its lowest level since last April. “We expect a transition back toward fundamentals following a period dominated by positioning and flow-driven price action,” wrote Scott Rubner , head of equity and equity derivatives strategy at Citadel Securities in a note to clients on Tuesday. He added that investors are increasing their gross exposure to equities and options while limiting their directional risk. Reduced Exposure At the same time, systematic investors cut exposure to stocks amid market uncertainty, raisin...
ImmunityBio press release ( IBRX ): Q1 revenue of $44.2M beats by $1.03M . Preliminary net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 ANKTIVA Unit Growth: 168% increase in unit sales volume in Q1 2026 compared to Q1 2025 The Company ended the quarter with an estimated $380.9 million in cash, cash equivalents, and marketable s...
ImmunityBio press release ( IBRX ): Q1 revenue of $44.2M beats by $1.03M . Preliminary net product revenue of approximately $44.2 million, representing an ~168% year-over-year increase compared with Q1 2025 ANKTIVA Unit Growth: 168% increase in unit sales volume in Q1 2026 compared to Q1 2025 The Company ended the quarter with an estimated $380.9 million in cash, cash equivalents, and marketable securities as of March 31, 2026. More on ImmunityBio ImmunityBio: No Need To Rush Into Buying Today - Why I'm Downgrading To Hold ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript Immunity Bio responds to FDA concerns over Anktiva marketing materials ImmunityBio secures $75M financing under Oberland deal
JHVEPhoto Eli Lilly ( LLY ) announced on Thursday that its newly approved weight loss pill Foundayo (orforglipron) will be available across U.S. retail pharmacies starting today, setting up a battle with Novo Nordisk ( NVO ), which launched its rival Wegovy pill earlier this year. When the FDA approved the once-daily therapy for obese or overweight adults with weight-related medical problems earli...
JHVEPhoto Eli Lilly ( LLY ) announced on Thursday that its newly approved weight loss pill Foundayo (orforglipron) will be available across U.S. retail pharmacies starting today, setting up a battle with Novo Nordisk ( NVO ), which launched its rival Wegovy pill earlier this year. When the FDA approved the once-daily therapy for obese or overweight adults with weight-related medical problems earlier this month, the company began to immediately accept Foundayo prescriptions through its direct-to-consumer site, LillyDirect. Subsequently, the availability expanded to telehealth providers, and now shipments to nationwide retail pharmacies have also started. The Indiana-based drugmaker is selling Foundayo at $149 for a monthly supply of its lowest dose for cash-paying customers. Foundayo’s broader availability is set to further intensify the company’s ongoing battle with Novo ( NVO ) to dominate the market for oral weight loss drugs. Since the rollout of the Wegovy pill in January, the Danish drugmaker has launched a subscription program that allows cash-paying patients to receive a 3-, 6-, or 12-month supply of the Wegovy injection and Wegovy pill at a discounted price through telehealth providers. More on Eli Lilly 3 Reasons To Buy Eli Lilly Now Eli Lilly's Centessa Deal Shows It Is Awake To New Narcolepsy Reality Novo Nordisk Vs. Eli Lilly: Cheap Vs. Expensive, But No Clear Opportunity Cheap semaglutide copies in India challenge Novo Nordisk, cut Eli Lilly’s lead: report CEO of top pharma lobby PhRMA to resign: Endpoints News
The Philippines said Chinese forces fired flares directly at its coast guard aircraft over the Spratly Islands in the disputed South China Sea, calling the incident “a clear and deliberate act of bullying.” The Philippine Coast Guard was conducting routine monitoring over Mischief Reef and Subi Reef on Thursday when Chinese forces fired the flares, according to its spokesman, Rear Admiral Jay Tarr...
The Philippines said Chinese forces fired flares directly at its coast guard aircraft over the Spratly Islands in the disputed South China Sea, calling the incident “a clear and deliberate act of bullying.” The Philippine Coast Guard was conducting routine monitoring over Mischief Reef and Subi Reef on Thursday when Chinese forces fired the flares, according to its spokesman, Rear Admiral Jay Tarriela . The Chinese also issued radio transmissions, claiming “indisputable sovereignty” over the areas, he said. “These reckless and aggressive actions by China represent yet another escalation in their campaign of intimidation and harrassment,” Tarriela said in a post on X . China’s embassy in Manila didn’t immediately respond to a request for comment. The Philippines and China have overlapping claims in the South China Sea, a strategic waterway believed to be rich in natural resources. The Southeast Asian nation has bolstered military ties with the US to help safeguard its claims in the disputed sea, leading to repeated clashes between Chinese and Philippine ships. In an interview with Bloomberg Television last month, Philippine President Ferdinand Marcos Jr. signaled he’s open to restarting talks with Beijing on a joint oil and gas project in the disputed seas, saying the war in Iran may provide the impetus for a breakthrough .
Fossil Group (FOSL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Fossil Group (FOSL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.